EHAB vs. AHCO, AVAH, CHE, OPCH, AMED, BTSG, ADUS, GLPG, FUSN, and LMAT
Should you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include AdaptHealth (AHCO), Aveanna Healthcare (AVAH), Chemed (CHE), Option Care Health (OPCH), Amedisys (AMED), BrightSpring Health Services (BTSG), Addus HomeCare (ADUS), Galapagos (GLPG), Fusion Pharmaceuticals (FUSN), and LeMaitre Vascular (LMAT). These companies are all part of the "medical" sector.
Enhabit (NYSE:EHAB) and AdaptHealth (NASDAQ:AHCO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.
AdaptHealth received 74 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 59.23% of users gave AdaptHealth an outperform vote while only 12.00% of users gave Enhabit an outperform vote.
Enhabit has higher earnings, but lower revenue than AdaptHealth. Enhabit is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
Enhabit has a net margin of -7.95% compared to AdaptHealth's net margin of -21.45%. AdaptHealth's return on equity of 8.47% beat Enhabit's return on equity.
In the previous week, AdaptHealth had 7 more articles in the media than Enhabit. MarketBeat recorded 11 mentions for AdaptHealth and 4 mentions for Enhabit. Enhabit's average media sentiment score of 1.53 beat AdaptHealth's score of 0.36 indicating that Enhabit is being referred to more favorably in the media.
82.7% of AdaptHealth shares are held by institutional investors. 1.9% of Enhabit shares are held by insiders. Comparatively, 4.4% of AdaptHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Enhabit has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, AdaptHealth has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Enhabit presently has a consensus target price of $10.13, suggesting a potential upside of 10.17%. AdaptHealth has a consensus target price of $12.42, suggesting a potential upside of 30.98%. Given AdaptHealth's stronger consensus rating and higher probable upside, analysts plainly believe AdaptHealth is more favorable than Enhabit.
Summary
AdaptHealth beats Enhabit on 12 of the 18 factors compared between the two stocks.
Get Enhabit News Delivered to You Automatically
Sign up to receive the latest news and ratings for EHAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools